Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse
- 1 March 1999
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 54 (2), 147-157
- https://doi.org/10.1023/a:1006118828278
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extractsBritish Journal of Cancer, 1998
- Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancerBritish Journal of Cancer, 1997
- Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancerBritish Journal of Cancer, 1997
- Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancerBritish Journal of Cancer, 1997
- Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomasBritish Journal of Cancer, 1994
- Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerBreast Cancer Research and Treatment, 1993
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992
- Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast CancerSeminars in Thrombosis and Hemostasis, 1991
- Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancerFibrinolysis, 1990
- Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary reportCancer, 1988